CClinicalTrials.gg
Status unknownNCT03428035NEUPANOUpdated Oct 9, 2018

The Impact of a Neutral Formulated and Designed Package Insert on Nocebo-effect.

An interventional study of Package Insert in Orthopedic Surgery, sponsored by University of Witten/Herdecke. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by University of Witten/Herdecke · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background The nocebo effect describes the association between the expectation of negative effects, (e.g. side effects) and the actual occurrence of negative effects. Studies have shown that the nocebo effect can be influenced by (risk) communication. Till today there is no study that compares different types of information on adverse events regarding the strength of the nocebo effect.

Aim The aim of this pilot randomized controlled trial is to analyse the influence of different communication types on the frequency and intensity of adverse events and adherence. To increase the relevance and applicability of the results the study intervention builds up on package inserts because these are the most widespread form of information on side effects.

Methods Patients It is planned to include 60 patients in the study.

Intervention

  • Modified package insert: simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
  • Verbal information about side effects: The patient is informed verbally about side effects and does not receive any package insert.

Control Package insert according to EU (European Union) Directive 2001/83 / EC (European Commission) (usual package insert).

Outcomes

  • Number of patient reported adverse events (primary outcome).
  • Adherence (correct initiation of therapy, correct intake amount, premature discontinuation of therapy).
  • Resource use (e.g. provider contacts).

Type of study Monocentric, outcome assessor, three-arm, randomised controlled pilot trial.

02

Conditions studied

  • Orthopedic Surgery

Keywords

  • Randomized controlled trial
  • package insert
  • nocebo
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • elective orthopaedic surgery
  • planned intake of ibuprofen 600 mg to treat postoperative pain
  • postoperative pain medication other than Ibuprofen 600 (Opioids, Opiate, Paracetamol) no longer than 1-2 days postoperative (until discharge)
  • at least 18 years
  • able to speak German
  • no cognitive deficits
  • written informed consent

Exclusion criteria

Exclusion Criteria:

  • serious comorbidity
  • pain medication prior to surgery
  • other medication with similar side effects
  • polytrauma
  • planned inpatient rehabilitation > one week after hospital discharge
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Modified Package Insert

    Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.

    Other: Package Insert

  • No intervention
    Verbal Information

    The patient is informed verbally about side effects and does not receive any package insert.

  • Active comparator
    Control

    Package insert according to EU Directive 2001/83 / EC (usual package insert)

    Other: Package Insert

Interventions

  • OtherPackage Insert

    Modified package insert of Ibuprofen given postprocedural as pain medication

    Also known as: Patient Education

05

What researchers measure

Primary outcomes

  1. Number of patient reported adverse events

    Any reported adverse events

    Time frame: 6-9 days after surgery

Secondary outcomes

  1. Adherence

    Correct initiation of therapy, correct intake amount, premature discontinuation of therapy

    Time frame: 6-9 days after surgery

  2. Resource use

    e.g. provider contacts

    Time frame: 6-9 days after surgery

06

Study locations

1 site
  • Clinic for orthopedics, trauma surgery and sports traumatology, hospital Cologne Merheim
    Cologne, North-Rhine-Westfalia 51109, Germany
07

References and documents

Publications

  • Prediger B, Meyer E, Buchter R, Mathes T. Nocebo effects of a simplified package leaflet compared to unstandardised oral information and a standard package leaflet: a pilot randomised controlled trial. Trials. 2019 Jul 26;20(1):458. doi: 10.1186/s13063-019-3565-3. PubMed 31349865 ↗

Individual participant data

Plan to share: Yes — Study protocol and clinical study report will be shared as supplement with the journal publication

Supporting information: Study protocol, Csr

08

Registry details

Key details

Study ID
NCT03428035
Lead sponsor
University of Witten/Herdecke
Collaborators
German Research Foundation
Responsible party
Tim Mathes (Dr. Tim Mathes, University of Witten/Herdecke) — Principal investigator
First posted
Feb 9, 2018
Start date
Apr 1, 2018
Primary completion
Sep 30, 2018
Completion
Dec 31, 2018 (estimated)
Last update
Oct 9, 2018

Study contacts

Tim Mathes, Dr.
principal investigator · Witten/Herdecke University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion